The company's growth was meteoric. By 2018, it had attracted millions of customers and secured partnerships with pharmaceutical giants like GlaxoSmithKline. The crowning achievement came in June 2021 when 23andMe went public through a special purpose acquisition company (SPAC) merger, valuing the company at a staggering $6 billion.